Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Free full text

Full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Comparative Study

Clinical Trial, Phase I

Clinical Trial

Randomized Controlled Trial

Research Support, N.I.H., Extramural

Clinical Trial, Phase II

Review

Multicenter Study

Publication Year

From

Quick links

Individual year

2023

2022

2021

2018

2016

2015

2013

2012

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Toll-Like Receptor 8""[mesh_terms]

14 Results

Searching titles within these results

Identification of new potent agonists for toll-like receptor 8 by virtual screening methods, molecular dynamics simulation, and MM-GBSA.

Farideh Sadeghkhani, Zahra Hajihassan, Sajjad Gharaghani

Journal of biomolecular structure & dynamics 2023;41(19):10026-10036

Full Text

Abstract

Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8.

Xiaoyu Wang, Yu Chen, Steven Zhang, Jinxia Nancy Deng

PloS one 2022;17(4):e0260565

Free Full Text

Abstract

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.

Verena Turco, Kira Pfleiderer, Jessica Hunger, Natalie K Horvat, Kianush Karimian-Jazi, Katharina Schregel, Manuel Fischer, Gianluca Brugnara, Kristine Jähne, Volker Sturm, Yannik Streibel, Duy Nguyen, Sandro Altamura, Dennis A Agardy, Shreya S Soni, Abdulrahman Alsasa, Theresa Bunse, Matthias Schlesner, Martina U Muckenthaler, Ralph Weissleder, Wolfgang Wick, Sabine Heiland, Philipp Vollmuth, Martin Bendszus, Christopher B Rodell, Michael O Breckwoldt, Michael Platten

Nature communications 2023;14(1):771

Free Full Text

Abstract

Integrativesubtractive proteomics, immunoinformatics, docking, and simulation approaches reveal candidate vaccine against Sin Nombre orthohantavirus.

Alhumaidi B Alabbas

Frontiers in immunology 2022;13():1022159

Free Full Text

Abstract

Microparticles derived from obese adipose tissue elicit a pro-inflammatory phenotype of CD16, CCR5 and TLR8 monocytes.

Mariana Renovato-Martins, Maria Eline Matheus, Isadora Ramos de Andrade, João Alfredo Moraes, Simone Vargas da Silva, Marta Citelli Dos Reis, Antônio Augusto Peixoto de Souza, César Cláudio da Silva, Eliete Bouskela, Christina Barja-Fidalgo

Biochimica et biophysica acta. Molecular basis of disease 2018;1863(1):139-151

Free Full Text

Abstract

Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study.

Maria Juncal-Ruiz, Laura Riesco-Davila, Javier Vazquez-Bourgon, Victor Ortiz-Garcia de la Foz, Jacqueline Mayoral-Van Son, Rosa Ayesa-Arriola, Esther Setien-Suero, Juan Carlos Leza, Marcos Lopez-Hoyos, Benedicto Crespo-Facorro

International journal of molecular sciences 2021;21(17):6106

Free Full Text

Abstract

Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1.

Stephen A Spector, Grant R Campbell

PLoS pathogens 2013;8(11):e1003017

Free Full Text

Abstract

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Donald W Northfelt, Ramesh K Ramanathan, Peter A Cohen, Daniel D Von Hoff, Glen J Weiss, Gregory N Dietsch, Kristi L Manjarrez, Tressa D Randall, Robert M Hershberg

Clinical cancer research : an official journal of the American Association for Cancer Research 2015;20(14):3683-91

Full Text

Abstract

Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs.

Mouldy Sioud

Methods in molecular biology (Clifton, N.J.) 2015;1218():301-19

Full Text

Abstract

Profiling of the three circulating monocyte subpopulations in human obesity.

Estelle F Devêvre, Mariana Renovato-Martins, Karine Clément, Catherine Sautès-Fridman, Isabelle Cremer, Christine Poitou

Journal of immunology (Baltimore, Md. : 1950) 2015;194(8):3917-23

Full Text

Abstract

Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.

Juandy Jo, Anthony T Tan, James E Ussher, Elena Sandalova, Xin-Zi Tang, Alfonso Tan-Garcia, Natalie To, Michelle Hong, Adeline Chia, Upkar S Gill, Patrick T Kennedy, Kai Chah Tan, Kang Hoe Lee, Gennaro De Libero, Adam J Gehring, Christian B Willberg, Paul Klenerman, Antonio Bertoletti

PLoS pathogens 2015;10(6):e1004210

Free Full Text

Abstract

Autoinhibition and relief mechanism by the proteolytic processing of Toll-like receptor 8.

Hiromi Tanji, Umeharu Ohto, Yuji Motoi, Takuma Shibata, Kensuke Miyake, Toshiyuki Shimizu

Proceedings of the National Academy of Sciences of the United States of America 2016;113(11):3012-7

Free Full Text

Abstract

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Hailing Lu, Gregory N Dietsch, Maura-Ann H Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C Maino, Katherine E Henderson, James Jeffry Howbert, Mary L Disis, Robert M Hershberg

Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):499-509

Full Text

Abstract

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Laura Q M Chow, Chihiro Morishima, Keith D Eaton, Christina S Baik, Bernardo H Goulart, Leslie N Anderson, Kristi L Manjarrez, Gregory N Dietsch, James Kyle Bryan, Robert M Hershberg, Mary L Disis, Renato G Martins

Clinical cancer research : an official journal of the American Association for Cancer Research 2018;23(10):2442-2450

Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Toll-Like Receptor 8""[mesh_terms]

Identification of new potent agonists for toll-like receptor 8 by virtual screening methods, molecular dynamics simulation, and MM-GBSA.

Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8.

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.

Integrativesubtractive proteomics, immunoinformatics, docking, and simulation approaches reveal candidate vaccine against Sin Nombre orthohantavirus.

Microparticles derived from obese adipose tissue elicit a pro-inflammatory phenotype of CD16, CCR5 and TLR8 monocytes.

Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study.

Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1.

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs.

Profiling of the three circulating monocyte subpopulations in human obesity.

Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.

Autoinhibition and relief mechanism by the proteolytic processing of Toll-like receptor 8.

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Results for
""Toll-Like Receptor 8""[mesh_terms]